S_mmary The FONICAP group is screening, with randomised phase II studies. the activity of new chemotherapy programmes for advanced non-small-cell lung cancer (NSCLC) looking for regimens with >30% activity. In the present study. three regimens were tested: MIP (mitomycin 6mgm-2, ifosfamide 3 m-, cisplatinum 80mg m-2 on day every 28 days); MIP-IFN (MIP and interferon alpha-2b 3 MU s.c. three times a week); and PC (cisplatinum 60 mg m-' and carboplatin 400 mg m on day I every 28 days). Overall 93 chemotherapy-naive patients were enrolled: 23 received MIP, 27 received MIP-IFN and 43 received PC. Eighty per cent of the patients had stage IV and 20% stage Illb disease (positive pleural effusion or supraclavicular nodes). Response rates were as follows: MIP = 9% (95% CI 1-28%), MIP-IFN = 7% (95% CI 1-24%) and PC = 14% (95% CI 5-28%). The overal median survival was 183 days. Grade III-IV leucopenia was observed in 36% of patients treated with MIP-IFN vs 10% in the other two arms, and thrombocytopenia grade III-IV was reported in nearly 10% of patients overall. In conclusion, (1) all three regimens investigated have poor activity (<30%); (2) when tested in multicentre randomised phase II trials. MIP displays lower activity than in phase II trials; (3) PC has similar activity to other platinum-containing regimens; (4) randomised phase II studies are a reliable and quick method of determining the anti-tumour activity of novel chemotherapeutic regimens in NSCLC.
Although more than 50 agents have been tested in the last two decades, only a few of them have demonstrated discernible anti-tumour activity in the treatment of advanced-stage non-small-cell lung cancer (NSCLC). These antineoplastic drugs, including cisplatinum (CDDP), ifosfamide (IFX), mitomycin C (MMC), vindesine (VDS), vinblastine (VLB) and etoposide (VP16), produce 5-20% objective response rates when administered as single agents. Their use in combination regimens allows an increase in the objective response rate (20-40%) to be obtained without a detectable improvement in the survival outcome. Randomised phase III studies comparing the activity of the different chemotherapy programmes available have led to the conclusion that the known two-and three-drug regimens, including intermediate/highdose CDDP, have similar efficacy (Ihde, 1992) . Furthermore, the activity of these regimens in randomised multicentre phase III trials usually turns out to be lower than anticipated from the results of single-institution phase II studies (Einhorn et al., 1986) . Therefore, at the present time, it appears that the demonstration of significant activity in an uncontrolled phase II trial, often carried out in a very selected patient population, is not sufficient to warrant the initiation of an expensive and time-consuming large randomised phase III trial.
Based on these considerations, in 1991 the Italian Lung Cancer Task Force (FONICAP) started a policy of screening and verification of the anti-tumour activity of new and promising chemotherapy regimens or single agents with consecutive multicentre phase II randomised trials. This study design should allow us to overcome the selection bias most likely responsible for the overestimation of chemotherapy Correspondence: A Ardizzoni. Department of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro. V. le Benedetto XV, 10 16132 Genoa. Italy activity in non-randomised phase II studies. Only those programmes which show significant anti-tumour activity in this setting may deserve to be compared with standard treatments in phase III studies. The present study was aimed at assessing the activity and toxicity of three CDDP-containing chemotherapies: MMC-IFX-CDDP (MIP), MIP combined with recombinant interferon alpha (MIP-IFN) and carboplatin-CDDP (CP).
In the first arm, we aimed at verifying the activity of MIP, which showed a high level of activity in four non-randomised phase II studies (37-69% response rate) (Giron et al., 1987; Cullen et al., 1988; Currie et al.. 1990; Mariani et al., 1991) .
Recombinant interferon (IFN) was added to MIP in the second arm of the study according to the hypothesis resulting from a previous randomised phase III trial of our group (Ardizzoni et al., 1993) , suggesting a possible potentiating effect of IFN on CDDP-containing chemotherapy.
The third arm, in view of the single-agent activity, different toxicity profile and incomplete cross-resistance of the two agents, consisted of a combination of carboplatin (CBDCA) and CDDP in an attempt to administer a 'high-dose platinum monotherapy' with acceptable toxicity (Piccart et al., 1990 
Treatment
Patients were randomised to one of the following treatment arms:
Mesna 600 mg m-2 i.v. before IFX infusion and 1200mgm-2 p.o. 4 and 8h after IFX Arm B The same as in arm A plus recombinant IFN-a2b 3 000 000 IU subcutaneously daily from day -2 to day + 3 then 3 days a week.
Arm C CDDP 60mgm-' i.v. on day 1 CBDCA 400 mgm-2 i.v. on day I Cycles were repeated every 28 days. In the case of incomplete haematologial recovery, treatment was delayed by 1 week. In the case of nadir grade IV haematological toxicity, a 25% dose reduction was applied. All patients had to be given at kast two courses of chemotherapy unless rapid progression, excessive toxicity or rapid clinical deterioration occurred. Treatment was continued for a maximum of six cycles provided progression did not occur.
Cisplatinum, in the three treatment arms, was infused rapidly over 15 min preceded by 500 ml of normal saline over 30 min and followed by 1000 ml of normal saline containing 1 g of magnesum sulphate over 60-90 min-If diuresis was <200 ml at the end of the infusion, furosemide 20mg i.v. was administered, followed by 500 ml of normal sahne until acceptable diuresis was achieved. All randomised patients were included in the final analysis of response rate on an 'intention to treat' basis, thereby including also early deaths and early progressions.
Resdt
Patient demographics Ninety-three patients were entered into the study from 12 Italian institutions. The characteristics of patients are shown in Table I . Accrual in arms A and B was stopped at the first stage as the minimum number of responses required to proceed to the second stage of the study was not achieved. By the time the first 18 patients had all been evaluated for response, a total of 23 and 27 had been enrolled in arms A and B respectively. Patient intake in arm C could proceed through the second stage and, as a consequence, 43 patients were randomised in this arm of the study.
The majority of patients were males (nearly 90%), were ambulatory (ECOG performance status 0-1) and had stage IV disease. Median age was 61 years in arm A (range 32-70), 60 years in arm B (range 39-70) and 62 years in arm C (range 36-70). There was a slight disproportion in favour of arm A in terms of stage (Ilb vs IV) and histology (squamous vs adenocarcinoma). The most frequent sites of metastases were bone (41%), superficial nodes (29%), lung (23%) and adrenals (18%).
Analysis of activity
All randomised patients were included in the response analysis, according to the 'intention to treat' principle. 'Delivered' and 'planned' dose intensity were calculated at the second and fourth cycle using the standard methodology (Hryniuk, 1984) . At the second cycle 14, 17 and 31 patients in arms A, B and C, respectively, could be evaluated for the calculation of dose intensity. All these patients actually received more than 60% of the planned dose intensity. The explore them further and launch randomised phase m studie comparing the outcome of patients treated with these novel combinations vs standard regimes. The activity of MIP was lower than that reported in previous studies. In fact, the response rate of MIP in nonrandomised phase II studies (Giron et al., 1987; Cullen et al., 1988; Currie et al., 1990; Mariani et al., 1991) was always reported to be greater than 30% (37-69%) whereas, in the present study, the anti-tumour activity was clearly lower. This discrepancy may arise for a number of reasons: the selection of patients with more advanced disease (higher proportion of patients with stage IV disease), the strict methodology used to assess response and the use of an "intention to treat' analysis (unevaluable patients were included in the denominator for aculating major response rate). However, it is our opinion that MWP activity was overestimated in previous phase H studies, as is often the case for single-institution phase II compared with multicentre phase Il studies (Einhorn et al., 1986) . This strengthens the validity of the randomised phase H design as a more reliable tool to screen the activity of novel treatments. There are many advantages with studies of this type. Firsty, randomisation ensures that patients are centrally registered before treatment starts. This is essential to check eligibility and to ensure that all patients enroLled are reported upon. Second, patient selection, response criteria, dose modifications and reporting procedures are homogeneous among the participating centres. Finally, the central rview of radiological material allows the inter-observer vanability in response asssment to be reduced.
The addition of IFN to MIP did not improve the response rate. This is in contrast to one of our previous randomised studies, which showed an increased response rate when IFN was added to PEC chemotherapy (8.7% vs 21.5%) (Ardizzoni et al., 1993) . Given the low activity of PEC in that study, we aimed at exploring the potentiating activity of IFN with a more recent, and presumably more active, regimen. However, the results of the present study would not suggest a potentiating effect of IFN on MIP chemotherapy. This might be because of lower dose of IFN used in this study (3 MU compared with 5 MU in the previous study).
CDDP and CBDCA possess similar single-agent activity in advanced NSCLC (Bonomi et al., 1989) with different doselimiting toxicities. Although they share a common active metabolite and therefore a common mechanism of antitumour action, they have distic pharmacodynamics and additive cytotoxicity in lung cancer cell lines (Hong et al., 1985; Roed et al., 1988; Cohen et al., 1989) . Therefore, in theory, the combination of CDDP and CBDCA might enable the delivery of a high total dose of 'platinum' and an enhanced tumour cell kill, without producing excessive addictive toxcity. The activity of this combination in our study is similar to that of other CDDP-containing rimens. Interestingly, toxiity was unexpetdly mild, with only 10% of the patients having grade 3-4 leucopenia or thrombocytopenia and virtually no case of complete alopecia-Our results are similar to those of two other studies. A CALGB phase II trial reported a response rate of 13% among 76 extensive NSCLC patients (Kreisman et al., 1990) . Despite the use of slightly higher chemotherapy doses than in the American study, we observed a lower incidence of severe haematological toxicty. T-he European Lung Cancer Work-ing Party has recently published the results of a phase H randomised study of single-agent high-dose CDDP and moderate-dose CDDP combined with CBDCA. Although 50% less CBDCA was used in comparison with our study, they obtained a slightly better response rate (21%) with superimposable toxicity among 53 eligible patients (Scuier et al., 1994) . Therefore, CBDCA dose does not seem to play a major role in the activity and toxicity of the CDDP-CBDCA regimen.
In conclusion, none of the novel chemotherapy combinations under investigation in the present randomised phase II study appears to offer a significant therapeutic advantage over standard chemotherapy programmes. The combination of CBDCA and CDDP, given the low haematological and non-haematologial toxicity, can be considered as an alternative to standard platinum-containing regimens. Phase II randomised trials are a reliable and quick method of screening and verifying the anti-tumour activity of novel agents or combinations which may better orient the design of comparative phase III randomised studies in NSCLC.
